NCIC Clinical Trials Group

Members / Participants Membership Information Clinical Trials Meetings
&
Education
Publications

Lectures
Correlative Science / Tumour Bank Notices Fellowships Committees Papaya Mango EDC BARL
NCIC Clinical Trials Group / Cancer Clinical Trials Faculty Biographies
 
Elizabeth Eisenhauer, MD, FRCP(C)
Interim Director
Dr. Eisenhauer became Interim Director of the NCIC CTG in July, 2013. In 2012, she was named Head and Professor of the Department of Oncology at Queen’s University and Program Medical Director of the Cancer Centre of Southeastern Ontario at Kingston General Hospital. Prior to taking on these roles, Dr. Eisenhauer was Director of the NCIC CTG’s Investigational New Drug (IND) Program beginning in 1982 when the program was started. In this role, she was responsible for identifying and bringing into clinical trials novel cancer agents in Canada. Through her work in the IND Program, she directed the coordination of over 170 phase I, II and III trials across Canada, the US and Europe which included some of the first trials of paclitaxel and docetaxel, studies of topotecan, gemcitabine, various targeted antisense agents, angiogenesis inhibitors and small molecule signaling inhibitors.

Dr. Eisenhauer obtained her MD from Queen’s University in 1976 and subsequently completed Royal College of Physicians and Surgeons (Canada) training in both Internal Medicine and Hematology.
  Elizabeth Eisenhauer
 
Lesley Seymour, MD, FCP (SA), FRCP(C), PhD
Director IND
  Dr. Seymour completed training in Internal Medicine, Clinical Haematology & Medical Oncology and went on to complete her PhD, focusing on correlative studies and breast cancer. She took the position of Director of Medical Oncology at the Newfoundland Cancer Treatment and Research Foundation. In 1996 joined the Investigational New Drug Program at the NCIC CTG, and currently serves as the Director of the Program. Her primary interests are in early drug development and methodology and clinical research in lung cancer. She also holds the position of Professor and Medical Oncologist in the Department of Oncology at Queens University.
 
Penny Bradbury, MB, BCh, FRACP, MD
Senior Investigator
Dr. Bradbury is a medical oncologist; Assistant Professor within the Department of Oncology at Queen’s University and holds a Cancer Care Ontario Research Chair in Experimental Therapeutics. She is a graduate of Cardiff University Medical School, UK. She undertook specialist medical oncology training at the MidCentral Regional Cancer Treatment Service in New Zealand, and at the Cancer Research UK Medical Oncology Department, Churchill Hospital, Oxford, UK, obtaining the FRACP in 2005. She undertook fellowship training in Thoracic Oncology at Princess Margaret Hospital, Toronto, and a one year Drug Development Fellowship with the NCIC Clinical Trials Group, as part of The Terry Fox Foundation Training Program in Transdisciplinary Cancer Research at Canadian Institutes of Health Research. She has a research interest in the evaluation of new therapies for the management of thoracic malignancies and clinical trial methodology. Within the NCIC CTG, she is the Senior Investigator for the lung disease site and for National and International thoracic malignancy clinical trials.  
 
Judith-Anne W. Chapman, BSc, PhD, LFIBA, IOM, PStat, ON
Senior Biostatistician
  Dr. Chapman received her PhD in Statistics (Biometry) from the University of Waterloo (1974); and, did 3 years postdoctoral training, 2 as a Research Fellow of the NCIC. She worked in the teaching hospitals of the University of Toronto, and held an adjunct research appointment at the University of Waterloo from 1999-2005 before joining the NCIC CTG as Senior Biostatistician and the Department of Community Health and Epidemiology at Queen's. She specializes in transdisciplinary breast cancer research proposing statistical standardization of hormone receptor values, Her2 and ki67 and parametric survival analysis. Professionally, she spearheaded the formation of the Biostatistics Section of the Statistical Society of Canada (SSC), oversaw the implementation of SSC Accreditation of Professional Statisticians, assisted in establishment of American Statistical Assoiation (ASA) Accreditation, and serves on the ASA Accreditation Committee as well as being a SSC representative to International Accreditation Committee.
 
Bingshu Chen, MSc, PhD
Senior Biostatistician
Dr. Chen joined the NCIC CTG as senior biostatistician and faculty member with the Department of Community Health and Epidemiology at Queen's University in July 2008. Dr. Chen completed his PhD at the University of Waterloo, then spent 4 years at the US National Cancer Institute in the Division of Cancer Epidemiology and Genetics, first as a Postdoctoral Fellow and then as a Research Fellow. He has spent the last year as an Assistant Professor in the Department of Mathematics and Statistics at Concordia University. His research interests are survival analysis, design and analysis of clinical trials and epidemiology.  
 
Janet Dancey, MD, FRCP(C)
Director, Translational Research – Clinical
  In October 2008, Dr. Dancey took up her position as Director, Translational Research – Clinical. Prior to joining the NCIC CTG, Dr. Dancey was Senior Clinical Investigator in the Cancer Therapy Evaluation Program at the US National Cancer Institute and then Associate Chief of the Investigational Drug Branch. Dr. Dancey received her MD from the University of Ottawa and completed her residency training in internal medicine and medical oncology at the University of Toronto. In 1994-95, she was a research fellow with the NCIC CTG and continued her fellowship training at the Institut Gustave Roussy in France. Dr. Dancey has special expertise in new anti-cancer drug development, linking drug and biomarker development, and associated clinical trials methodology.
 
Keyue Ding, PhD
Senior Biostatistician
Dr. Ding received his PhD in Statistics in 1999 from the University of Alberta, and subsequently did postdoctoral training in the Department of Biostatistics at the University of Rochester. He joined the NCIC Clinical Trials Group and Department of Community Health & Epidemiology at Queen's in 2001. As a Senior Biostatistician at NCIC Clinical Trials Group, his primary responsibilities are the design and analysis of the cancer clinical trials conducted by the Group. Dr. Ding is also interested in sequential analysis; statistical quality control procedures; and, statistical computing.  
 
Christopher O'Callaghan, DVM, MSc, PhD
Senior Investigator
  Dr. O'Callaghan received his Doctorate in Veterinary Medicine and MSc and PhD degrees from the University of Guelph. He became a Senior Investigator with the NCIC CTG in 2001 and oversees the Gastrointestinal and Brain Site Committees and is an Associate Professor in the Department of Community Health & Epidemiology. His research interests are diverse and include clinical trials design and methodology and infectious disease epidemiology. In addition to his duties with Queen's University and the NCIC CTG Dr. O'Callaghan is a member of the Provincial Infectious Diseases Advisory Committee (PIDAC) Surveillance Subcommittee providing expert advice on infectious diseases to Public Health Ontario.
 
Wendy R. Parulekar, MD, FRCP(C)
Senior Investigator
Dr. Parulekar is a graduate of the University of Ottawa Medical School where she also completed residency training in Internal Medicine and Medical Oncology (1996). This was followed by a fellowship in Clinical Pharmacology at the Toronto-Sunnybrook Regional Cancer Centre. Since 1999, she has held a joint clinical/research position at Queen's University. Within the NCIC CTG, she acts as Senior Investigator for national and international studies in melanoma, as well as carcinoma of the breast, head and neck, and genitourinary system. Other interests include issues relating to clinical trial design and conduct, as well as the challenges and opportunities in clinical trials involving developing nations.   Wendy Parulekar
 
Harriet Richardson, BSc, MSc, PhD
Senior Investigator
  Dr. Harriet Richardson received her PhD in Epidemiology & Biostatistics at McGill University, where she studied the natural history of HPV infections and cervical neoplasia. She is Assistant Professor in the Department of Community Health & Epidemiology and joined the NCIC CTG in 2004 where she is the current Senior Investigator for the Quality of Life Committee and provides oversight for the trials with a focus on breast cancer prevention. Her research also involves tissue and blood banking for future biomarker development projects and evaluating quality of life data from clinical trials. Dr. Richardson who bridges the Division of Cancer Clinical Trials (NCIC CTG) and Cancer Care and Epidemiology in the Queen’s Cancer Research Institute also conducts etiologic research primarily focused on understanding specific environmental causes of breast cancer and their interaction with genetic and hormonal factors and elucidating intermediate mechanisms in the causal pathway to breast cancer.
 
Lois Shepherd, MDCM, FRCP(C)
Senior Investigator
Dr. Shepherd is a Professor in the Department of Pathology & Molecular Medicine. She completed her medical school training at McGill and spent three years in England where her interest in hematology developed. She completed her training as a Hematopathologist at the University of Ottawa and came to Kingston in 1987. Dr. Shepherd is currently the Director of the Transfusion Medicine Service & Immunology at Kingston General Hospital. Since 1989, Dr. Shepherd has worked with the NCIC CTG as a Senior Investigator. Her focus has been in Hematology and Breast Cancer as well as the development of the National Tumour/Tissue Repository associated with the CTG and correlative studies in clinical trials.  
 
Dongsheng Tu, BSc, PhD
Senior Biostatistician
  Dr. Tu is a Senior Biostatistician in the NCIC CTG with appointments in both the Departments of Community Health & Epidemiology, and Mathematics & Statistics. He came to Queen's in 1996 from the Therapeutic Products Directorate of Health Canada. His primary responsibilities are the design, management and analysis of the cancer clinical trials. He is also interested in the methodological research on the development and evaluation of statistical procedures for the design and analysis of cancer clinical trials and maintains an interest in the general mathematical theory of statistics.
Use this to link back to CTG home only

If you have any questions, comments or suggestions, please contact our